Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation

Experimental Cell Research

Volumn 312, Issue 15, 2006, Pages 2933-2941

  Colleselli, Daniela ^a   Bijuklic, Klaudija ^b   Mosheimer, Birgit A ^b   Kähler, Christian M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Cox 2; Endothelial progenitor cells; Proliferation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLSALICYLIC ACID; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOBENE; DICLOFENAC; PROTEIN KINASE B;

ANALYTIC METHOD; ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; WESTERN BLOTTING;

EID: 33747377104     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.05.021     Document Type: Article

References (27)

1. Needleman P., Jakschik B.A., Turk J., Morrison A.R., and Lefkowith J.B. Arachidonic acid metabolism. Annu. Rev. Biochem. 55 (1986) 69-102
2. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7916
3. Diaz A., Chepenik K.P., Korn J.H., Reginato A.M., and Jimenez S.A. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp. Cell Res. 241 (1998) 222-229
4. Yuan A., Yu C.J., Shun C.T., Luh K.T., Kuo S.H., Lee Y.C., and Yang P.C. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int. J. Cancer 115 (2005) 545-555
5. Fang H.Y., Lin T.S., Lin J.P., Wu Y.C., Chow K.C., and Wang L.S. Cyclooxygenase-2 in human non-small cell lung cancer. Eur. J. Surg. Oncol. 29 (2003) 171-177
6. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., and Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58 (1998) 3761-3764
7. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., and Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58 (1998) 4997-5001
8. Koki A.T., Leahy K.M., and Masferrer J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs 8 (1999) 1623-1638
9. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., and Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999) 1418-1423
10. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 (2000) 1306-1311
11. Chang Y.S., di T.E., McDonald D.M., Jones R., Jain R.K., and Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14608-14613
12. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., and Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
13. Hilbe W., Dirnhofer S., Oberwasserlechner F., Schmid T., Gunsilius E., Hilbe G., Woll E., and Kahler C.M. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J. Clin. Pathol. 57 (2004) 965-969
14. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., and Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62 (2002) 625-631
15. Niederberger E., Manderscheid C., Grosch S., Schmidt H., Ehnert C., and Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem. Pharmacol. 68 (2004) 341-350
16. Yazawa K., Tsuno N.H., Kitayama J., Kawai K., Okaji Y., Asakage M., Sunami E., Kaisaki S., Hori N., Watanabe T., Takahashi K., and Nagawa H. Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest. Int. J. Cancer 113 (2005) 541-548
17. Yang H.M., Kim H.S., Park K.W., You H.J., Jeon S.I., Youn S.W., Kim S.H., Oh B.H., Lee M.M., Park Y.B., and Walsh K. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110 (2004) 301-308
18. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., and Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62 (2002) 029-2033
19. Jamur M.C., Grodzki A.C., Moreno A.N., de Mello L.F., Pastor M.V., Berenstein E.H., Siraganian R.P., and Oliver C. Identification and isolation of rat bone marrow-derived mast cells using the mast cell-specific monoclonal antibody AA4. J. Histochem.Cytochem. 49 (2001) 219-228
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
21. Kahler C.M., Herold M., Reinisch N., and Wiedermann C.J. Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts. J. Cell Physiol. 166 (1996) 601-608
22. Pelosi E., Valtieri M., Coppola S., Botta R., Gabbianelli M., Lulli V., Marziali G., Masella B., Muller R., Sgadari C., Testa U., Bonanno G., and Peschle C. Identification of the hemangioblast in postnatal life. Blood 100 (2002) 3203-3208
23. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., and Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin.Cancer Res. 5 (1999) 1001-1005
24. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., Ferrara C.A., Yankelevitz D.F., Subbaramaiah K., Pasmantier M.W., and Dannenberg A.J. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21 (2003) 2645-2650
25. Masferrer J.L., Koki A., and Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann. N. Y. Acad. Sci. 889 (1999) 84-86
26. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15 (2001) 2057-2072
27. Bompais H., Chagraoui J., Canron X., Crisan M., Liu X.H., Anjo A., Tolla-Le Port C., Leboeuf M., Charbord P., Bikfalvi A., and Uzan G. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 103 (2004) 2577-2584